Fine Foods & Pharmaceuticals N.T.M. SpA
MMIL:FF6.24
EUR
-0.20
(-3.11%)
Fine Foods & Pharmaceuticals N.T.M. SpA
MIL:FF
(Euronext Milan)
Recent
price
6.24
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.- Similar Companies
- Business
- Fine Foods & Pharmaceuticals N.T.M. S.p.A. (FF.MI) operates as an independent Italian contract development and manufacturing organization (CSDMO) specializing in the production of solid oral forms for pharmaceuticals, nutraceuticals, cosmetics, medical devices and biocides; its core offerings encompass powders, soluble and effervescent granules, film-coated, effervescent, chewable and fast-melting tablets, hard gelatine capsules and sachets, sticks, blisters, jars, tubes and bottles across therapeutic areas including probiotics, multivitamins, minerals, immune support, sleep aids, gastrointestinal, circulatory, osteoarticular, urinary, women's health, beauty, healthy ageing and mental wellbeing, with specific active pharmaceutical ingredients such as paracetamol, ibuprofen, diclofenac, pantoprazole, nebivolol hydrochloride, folic acid, chondroitin sulfate and over 80 others; nutraceuticals represent the largest segment at approximately 58% of revenues, followed by pharmaceuticals at 31% and cosmetics at 11%, serving pharmaceutical, nutraceutical and cosmetic industries with branded and third-party products including innovative lines like Biotic3 postbiotic-probiotic-prebiotic combinations and Fizzy & Fast dissolvable tablets. Founded in 1984 and headquartered in Verdellino (Bergamo), Italy, the company employs around 779 people and maintains manufacturing facilities exceeding 14,200 square meters in the pharmaceutical segment alone, with over 100 production lines supporting operations in Italy, Germany, France, the United Kingdom, Spain, Greece and other international markets where roughly 50% of sales originate abroad. Recent developments include the June 2025 completion of a €30 million loan from Intesa Sanpaolo to expand the Brembate pharmaceutical plant, set for operational readiness by year-end 2025 with production starting in 2026 and a new mandatory third shift to address saturated capacity and new orders; a July 2025 rebranding of Euro Cosmetic to Fine Cosmetics under new leadership with managers Orietta Riccaboni, Paolo Colosio and Benedetta Suardi; an August 2024 preliminary agreement to acquire 21,000 square meters of land adjacent to the Zingonia-Verdellino nutraceutical facility for €4 million to boost nutra capacity with investments planned for 2025 and initial revenues in early 2026; the May 2025 unveiling of a new brand identity; the appointment of Pietro Oriani as CEO in 2024 with former CEO Giorgio Ferraris providing a three-year consultancy for transition; a third consecutive EcoVadis Platinum ESG rating in March 2025; the 2021 acquisitions of Pharmatek PMC and Euro Cosmetics to enter medical devices, biocides and cosmetics; and a transition from AIM Italia to Euronext STAR Milan in July 2021, alongside over €100 million in investments over five years driving an 11% average annual revenue growth rate over the past decade.